Galecto appoints Sherwin Sattarzadeh as COO; issues warrant to Paramora

Damora Therapeutics, Inc.

Sherwin Sattarzadeh appointed COO effective Jan 5, 2026; base salary $540,000, target bonus 40%.
Initial equity grant includes 190,376 RSUs and options for 444,209 shares vesting over four years.
Issued warrant to Paramora for 628,302 shares at $23.01 per share under Paragon Option Agreement.
Severance provisions: 12 months' salary (18 months if within Change in Control Period) plus accelerated vesting.

item 3.02 item 5.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Damora Therapeutics, Inc. issued up to 628,302 shares of warrant to Paramora Holding LLC.

Security: warrant
Shares: up to 628,302 shares
Purchaser: Paramora Holding LLC

Exact text from the filing

we issued to Paramora a warrant to purchase an aggregate of up to 628,302 shares of our common stock, with a per share exercise price equal to $23.01, which was the closing price of a share of the Company's common stock on December 31, 2025

View on SEC.gov

Browse all equity issuances →

Damora Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-003490

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.